Synthesis and Characterization of Process-Related Impurities of Antidiabetic Drug Linagliptin
Linagliptin, a xanthine derivative, is a highly potent, selective, long-acting and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. During the process development of linagliptin, five new process-related impurities were detected by high performance liquid chromatography (HPL...
Main Authors: | Yiwen Huang, Xiaoqing He, Taizhi Wu, Fuli Zhang |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado: |
MDPI AG
2016-08-01
|
Series: | Molecules |
Subjects: | |
Acceso en liña: | http://www.mdpi.com/1420-3049/21/8/1041 |
Títulos similares
-
Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan
por: Soulmaz Fazeli Farsani, et al.
Publicado: (2019-09-01) -
Renal insufficiency and linagliptin therapy: a case report
por: Anna Corsi, et al.
Publicado: (2018-09-01) -
Journey from EMPA-REG to CARMELINA to EMPEROR-Preserved: Empagliflozin/linagliptin in heart failure and diabetes
por: Sharvil S Gadve, et al.
Publicado: (2022-01-01) -
HPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application
por: Eman A. Bahgat, et al.
Publicado: (2023-03-01) -
Identification, synthesis, and characterization of potential genotoxic impurities of sildenafil citrate drug substance
por: P. Rajesh Reddy, et al.
Publicado: (2020-11-01)